Olodaterol for the treatment of asthma

References

• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2016 update). [ cited 2016 Apr 24]. Available at: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/
   Google Scholar
• British Thoracic Society. Scottish intercollegiate guidelines network. Br Guidel Manag Asthma Thorax. 2014;69(Suppl 1):1–192.
   Google Scholar
• Lougheed MD, Leniere C, Ducharme FM, et al. Canadian thoracic society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults: executive summary. Can Respir J. 2012;19:e81–8.
   PubMedGoogle Scholar
• National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma–summary report 2007. J Allergy Clin Immunol. 2007;120(5):S94–S138.
   Google Scholar
• Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327:1198–1203.
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034–1037.
   Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006 Jun 20;144(12):904–912.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Oleszczuk M, Stovold E, et al. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2012 Oct;17(10):CD010005.
   Google Scholar
• Cates CJ, Wieland LS, Oleszczuk M, et al. Safety of regular formoterol or salmeterol in adults with asthma: an overview of cochrane reviews. Cochrane Database Syst Rev. 2014 Feb;6(2):CD010314.
   Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010;362:1169–1171.
   PubMed Web of Science ®Google Scholar
• Patel M, Shaw D. A review of standard pharmacological therapy for adult asthma – steps 1 to 5. Chron Respir Dis. 2015;12:165–176.
   PubMed Web of Science ®Google Scholar
• Matera MG, Curradi G, Cazzola M. Long-acting beta(2) agonists in asthma and allergic rhinitis. Expert Opin Pharmacother. 2008;9:1531–1539.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;4:CD005535.
   Google Scholar
• Brozek JL, Kraft M, Krishnan JA, et al. Long-acting β2-agonist step-off in patients with controlled asthma. Arch Intern Med. 2012;172:1365–1375.
   PubMedGoogle Scholar
• Cazzola M, Segreti A, Matera MG. Novel bronchodilators in asthma. Curr Opin Pulm Med. 2010;16:6–12.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. β(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163:4–17.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Olodaterol hydrochloride. Drugs of Future. 2013;38:235–243.
   Web of Science ®Google Scholar
• Bouyssou T, Hoenke C, Rudolf K, et al. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20:1410–1414.
   PubMed Web of Science ®Google Scholar
• Striverdi® Respimat® (olodaterol) Inhalation Spray For Oral Inhalation. [ cited 2016 Mar 13]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Striverdi%20Respimat/striverdi.pdf
   Google Scholar
• Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53–62.
   PubMed Web of Science ®Google Scholar
• Naline E, Ostermann A, Devillier P, et al. β2 agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings [abstract]. Am J Respir Crit Care Med. 2010;181:A4443.
   Google Scholar
• Brown SM, Barnes PJ, Donnelly LE. Effect of olodaterol on the relaxation of small airways [abstract]. Eur Respir J. 2011;38:308s.
   Google Scholar
• Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337:600–609.
   PubMed Web of Science ®Google Scholar
• Lewis R, Chachi L, Amrani Y, et al. A comparison of β2-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells [abstract]. Eur Respir J. 2013;42(Suppl 57):P1589.
   Google Scholar
• Costa L, Roth M, Miglino N, et al. Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway. Pulm Pharmacol Ther. 2014;27:29–37.
   PubMed Web of Science ®Google Scholar
• Smit M, Zuidhof AB, Bos SI, et al. Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma. J Pharmacol Exp Ther. 2014;348:303–310.
   PubMed Web of Science ®Google Scholar
• Wex E, Bouyssou T. Olodaterol attenuates citric acid-induced cough in naïve and ovalbumin-sensitized and challenged guinea pigs. PLoS One. 2015;10:e0119953.
   PubMed Web of Science ®Google Scholar
• Freund-Michel VC, Birrell MA, Giembycz MA, et al. Beta2-agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway. Eur Respir J. 2010;35:647–654.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75:665–673.
   PubMed Web of Science ®Google Scholar
• Matera MG, Ora J, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. Ther Clin Risk Manag. 2015;11:1805–1811.
   PubMed Web of Science ®Google Scholar
• Borghardt JM, Weber B, Staab A, et al. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. Br J Clin Pharmacol. 2016;81:538–552.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Application number: 203108Orig1s000. Clinical pharmacology and biopharmaceutics review(s). [ cited 2016 Mar 13]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203108Orig1s000ClinPharmR.pdf
   Google Scholar
• Public Assessment Report of the Medicines Evaluation Board in the Netherlands. Striverdi Respimat 2.5 micrograms, solution for inhalation Boehringer Ingelheim International GmbH, Germany. [ cited 2016 March 6]. Available from: http://mri.medagencies.org/download/NL_H_2498_001_PAR.pdf
   Google Scholar
• O’Byrne PM, Van Der Linde J, Cockcroft DW, et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta2-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124:1217–21.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, D’Urzo T, Beck E, et al. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. Respir Res. 2015;16:97.
   PubMed Web of Science ®Google Scholar
• Beeh K-M, LaForce C, Gahlemann M, et al. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Respir Res. 2015;16:87.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax. 2012;67:342–349.
   PubMed Web of Science ®Google Scholar
• Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. US Food and Drug Administration Center for Drug Evaluation and Research (CDER). Joint meeting of the pulmonary-allergy drugs advisory committee, drug safety and risk management advisory committee and the pediatric advisory committee. [ updated 2008 Dec 10; cited 2016 Mar 7] Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf
   Google Scholar
• Cazzola M, Page CP, Rogliani P, et al. β2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187:690–696.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Sharafkhaneh A, Barber R, et al. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med. 2002;165:1353–1358.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Moore RH, Zimmerman JL, et al. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007;101:1007–1.
   PubMed Web of Science ®Google Scholar
• Charlton SJ. Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol. 2009;158:165–168.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Coppola A, Rogliani P, et al. Novel glucocorticoid receptor agonists in the treatment of asthma. Expert Opin Investig Drugs. 2015;24:1473–1482.
   PubMed Web of Science ®Google Scholar
• Bouyssou T, Casarosa P, Pieper M, et al. Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs [abstract]. Eur Respir J. 2011;38(Suppl 55):3451.
   Google Scholar